Sandostatin LAR now recommended for midgut tumours

Sandostatin LAR (octreotide), a synthetic derivative of somatostatin, is now also licensed for use in the treatment of advanced neuroendocrine tumours (NETs) of the midgut and where non-midgut sites of origin have been excluded but the primary origin is unknown.

In the double-blind, phase IIIb PROMID study (n=85), treatment-naïve patients with well-differentiated metastatic midgut NETs were randomised to receive monthly intramuscular octreotide LAR 30mg injections or placebo, using time to tumour progression (TTP) as the primary endpoint.

Median TTP was over twice as long for patients receiving octreotide as for those receiving placebo group: 14.3 months versus 6 months (hazard ratio 0.34; 95% CI 0.20-0.59; p<0.000072). However, this TTP increase was not associated with a significant difference in survival between the groups.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Calcium and Vitamin D Supplements for Osteoporosis

Calcium and Vitamin D Supplements for Osteoporosis

Formulations, doses and costs of osteoporosis supplements.

Asthma and COPD Preparations and Compatible Devices

Asthma and COPD Preparations and Compatible Devices

Available presentations of bronchodilators and anti-inflammatories.

Topical Steroids, Comparison of Potencies and Formulations

Topical Steroids, Comparison of Potencies and Formulations

Strengths and formulations of topical steroids.

Topical Steroids, Potential Skin Sensitisers as Ingredients

Topical Steroids, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in topical steroids.